TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05641532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention in persons newly diagnosed with MS
Description: 1. The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~2. The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (\~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~3. The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program.
Study: NCT05619458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: 6-week mindfulness intervention
Study: NCT05611073

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance, intermediate and near visual acuity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance, intermediate and near visual acuity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometric Data Collection
Description: Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometric Data Collection
Description: Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.

Intervention type: OTHER
Intervention: Patient Questionnaire
Description: Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.

Intervention type: OTHER
Intervention: Patient Questionnaire
Description: Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
Study: NCT06469463

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: The healthy subjects in the control group will perform an MRI head scan, which will be used to construct 3D head models and headcasts.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MEG
Description: The healthy subjects will undergo hpMEG data while wearing 3D-printed headcasts created from high resolution MRI

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EEG
Description: The healthy participants will undergo a similar session using EEG recording, using a Polhemus Fastrak system for localization of EEG electrodes and precise co-registration with anatomy and hpMEG data.~The patients group will take part in the same EEG recording session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: The healthy participants will undergo a similar session using EEG recording, using a Polhemus Fastrak system for localization of EEG electrodes and precise co-registration with anatomy and hpMEG data.~The patients group will take part in the same EEG recording session.
Study: NCT05585866

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
Study: NCT04362891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cosmetic lip augmentation
Description: The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cosmetic lip augmentation
Description: The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cosmetic lip augmentation
Description: The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cosmetic lip augmentation
Description: The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
Study: NCT04059965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panel Management for Anticoagulation Therapy
Description: Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive standard, protocolized care in their respective anticoagulation clinics
Study: NCT04850274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Therapy Intervention (RTI)
Description: A single ED session followed by 5 remote therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Remote Therapy Intervention
Description: Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
Study: NCT04785677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency in Stressful Experiences (RISE) Program
Description: The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
Study: NCT06231147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK
Description: horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror

Intervention type: OTHER
Group type: OTHER
Intervention: HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK
Description: horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
Study: NCT05214560

Intervention type: DEVICE
Intervention: Spinal needle
Description: Insertion of a spinal needle to perform the neuraxial procedure.
Study: NCT03764748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study: NCT05003635

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVEBRA device
Description: Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
Study: NCT05607238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Vascular Access - Midline catheter
Description: Ultrasound guided vascular access with a midline IV catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Vascular Access - peripheral IV
Description: Ultrasound guided vascular access with a peripheral IV catheter
Study: NCT06397768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT04786067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
Study: NCT04831060

Intervention type: PROCEDURE
Intervention: Periodontal treatment
Description: For Cases :~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal treatment~* At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~* At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* Maintenance~For Controls:~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days
Study: NCT06397768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT04181736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Tablets
Description: Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
Study: NCT05736029

Intervention type: OTHER
Intervention: blood, stool and tissue samples collection
Description: blood, stool and tissue samples collection before and during the treatment, as applicable

Intervention type: OTHER
Intervention: blood, stool and tissue samples collection
Description: blood, stool and tissue samples collection before and during the treatment, as applicable

Intervention type: OTHER
Intervention: blood, stool and tissue samples collection
Description: blood, stool and tissue samples collection before and during the treatment, as applicable
Study: NCT06219798

Intervention type: DIAGNOSTIC_TEST
Intervention: GFR
Description: Exit of the study due to death, dialysis, or transplantation
Study: NCT06151561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study: NCT05673538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00973-MS tablets treatment
Description: The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
Study: NCT04810702

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04361266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotium nanoscaffold
Description: Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control arm rotator cuff repair
Description: Standard rotator cuff repair without Rotium
Study: NCT05717257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
Study: NCT05791435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneuRIP
Description: Measuring respiratory indices through Respiratory Inductance Plethysmography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneuRIP
Description: Measuring respiratory indices through Respiratory Inductance Plethysmography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biofeedback to assist with breathing
Description: Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
Study: NCT05847062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
Study: NCT06593379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety planning
Description: Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety planning
Description: Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans
Study: NCT06219798

Intervention type: DIAGNOSTIC_TEST
Intervention: GFR
Description: Exit of the study due to death, dialysis, or transplantation

Intervention type: DIAGNOSTIC_TEST
Intervention: GFR
Description: Exit of the study due to death, dialysis, or transplantation
Study: NCT06593379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIST Intervention
Description: This is a mobile intervention designed to target and modify suicidal cognitions. Veteran in this condition will be asked to use the intervention 5 times a week for 4 weeks.
Study: NCT05420805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ALAC, inulin, FOS, and sodium butyrate
Description: Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium butyrate and zinc oxide
Description: Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
Study: NCT05245357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lentil
Description: Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lentil
Description: Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
Study: NCT06588478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirtobrutinib
Description: Administered Orally.
Study: NCT05738382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109
Description: oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109
Description: oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109
Description: oral administration once daily
Study: NCT06381661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
Study: NCT05738382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: 0.25 mg, Subcutaneous injection once daily.
Study: NCT06610682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat 150 MG [Tybost]
Description: Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles